![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The two companies plan to conduct gene corrections in ocular tissues using mCureX's mRNA technology and ToolGen's TGT-101 & CRISPR/Cas9 gene-editing technology for the treatment of rare hereditary eye diseases.
Lead Product(s): TGT-101
Therapeutic Area: Ophthalmology Product Name: TGT-101
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: mCureX
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 15, 2022